Ark Invest sold $11.2M in Twist Bioscience on June 30, the largest single-day trim this year. The sale funded buys in SoFi and Recursion. Twist reports next quarter in August.
Cathie Wood's Ark Invest sold $11.2 million in Twist Bioscience shares on June 30, the largest single-day reduction in the position this year. The sale of roughly 114,000 shares came through the Ark Innovation ETF and the Ark Genomic Revolution ETF.
The trim looks like routine portfolio rebalancing rather than a conviction break. Ark's two funds still held a combined $332 million in Twist as of July 15. The Genomic Revolution ETF held Twist as its third-largest position. Twist shares have rallied 190% in 2026.
On the same day Ark sold Twist, it bought $3.9 million of Circle Internet Group and $3.6 million of SoFi Technologies, according to the firm's daily trade notifications. The Ark funds also added $2.2 million in Recursion Pharmaceuticals. The pattern suggests Ark was freeing capital to rotate into newer or lagging positions.
The biggest driver of Ark's returns this year has been Nvidia, which carries an Alpha Score of 70 (Moderate) at $202.81, according to AlphaScala's risk framework. Twist is a smaller, higher-conviction bet within the genomics sleeve. The broader market has been calm by index measures. Beneath the surface, rotation is active. The selling in Twist fits that pattern.
Twist Bioscience prints synthetic DNA on silicon chips, a manufacturing method that cuts research costs for drug discovery and agricultural biotechnology. Amazon included Twist as a partner in its Amazon Bio Discovery application for testing new drugs. The company has posted 13 straight quarters of sequential revenue growth. It guided for 2026 revenue of $442 million to $447 million, up from $376.6 million in 2025.
The 190% gain this year leaves the stock exposed to any quarterly miss. Twist continues to report net losses. The valuation assumes the growth trajectory holds without interruption. For traders tracking the biotech rotation, the Ark flows offer a real-time signal of how a top active manager sizes exposure at current levels.
Twist reports fiscal third-quarter results in August. The company's guidance for 2026 implies an 18% growth rate at the midpoint, a bar the stock's current valuation has already priced in.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.